The Food and Drug Administration has tapped Vinay Prasad, a prominent critic of federal COVID-19 policies and a proponent of ...

The Food and Drug Administration says that a prominent medical contrarian and critic of the drug industry will head its ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Pfizer posts mixed first-quarter results, maintains annual forecast COVID vaccine sales better-than-expected, while sales of antiviral treatment decline Expects to save $7.7 billion in costs by ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street's revenue estimate, as sales of its COVID-19 ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled trials before they’re licensed for use, raising urgent questions about the ...

The new cuts come as the drugmaker struggles to find sources of growth amid declining demand for its vaccine and treatment for Covid-19. Pfizer is expected to lose more than $15 billion in revenue ...